U.S. market Closed. Opens in 8 hours 54 minutes

KNTE | Kinnate Biopharma Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for KNTE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak.

Valuation (14%)

Company Industry
P/E Ratio (TTM) -1.13 -22.80
PEG Ratio (TTM) -0.09 15.43
P/S Ratio (TTM) N/A 49.46
P/B Ratio (TTM) 0.78 18.73
P/FCF Ratio (TTM) -1.25 -3.36
Price to 5YR AVG Earnings Ratio -1.63 -3.37
Price to 5YR AVG FCF Ratio -2.05 -9.05

Profitability (0%)

Company Industry
ROA (TTM) -63.90% -5.26%
ROE (TTM) -59.00% 16.17%
Net Profit Margin (TTM) N/A -1,563.32%
ROIC 5YR AVG -85.16% 15.10%

Growth (25%)

4QTR AVG 3YR AVG 5YR AVG
EPS 12.25% -93.94% -60.32%
Revenue N/A N/A N/A
Net Income 10.43% -135.25% -86.42%
Cash Flow 5.59% -116.84% -77.64%

Health (47%)

Company Industry
Current Ratio (TTM) 13.19 6.16
Quick Ratio (TTM) 12.84 5.88
D/E Ratio (TTM) 0.02 -15.51
Interest Coverage (TTM) 70.63 -2.37
Piotroski F-Score 2 5
Altman Z-Score 1.09 14.06
LTL to 5YR AVG FCF -0.04 0.17
Shares Outstanding Growth 5YR AVG 61.71% 123.56%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙